Brief: European Study Provides More Evidence Supporting Icecure's Prosense® Is Safe & Effective Cryoablation Treatment For Metastatic And Recurrent Breast Cancer
09/07/2024 13:50
July 9 (Reuters) - Icecure Medical Ltd ICCM.O :
* EUROPEAN STUDY PROVIDES MORE EVIDENCE SUPPORTING ICECURE'S
PROSENSE® IS SAFE & EFFECTIVE CRYOABLATION TREATMENT FOR
METASTATIC AND RECURRENT BREAST CANCER
Source text for Eikon: ID:nPn1GlCzfa
Further company coverage: ICCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Icecure Medical
See all newsIcecure Medical Ltd reports results for the quarter ended June 30 - Earnings Summary
Israel's IceCure Medical H1 revenue rises on higher system, probe sales
Brief: Icecure Sio Petitions Nccn To Include Cryoablation In Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance Of Prosense®
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:45 AM